Australia's Antisense Therapeutics jumps on muscular dystrophy drug potential

Percheron Therapeutics

24/09/2021 06:44

** Shares of Australian biotech co  ANP.AX  jump as much as
7.5% to A$0.22, highest since Aug. 4 
    ** Co says study data found its drug ATL1102 to be an
exciting prospect for treatment of patients with Duchenne
muscular dystrophy (DMD), a muscle weakness disorder
 urn:newsml:reuters.com:*:nASX6MkLzQ 
    ** Study also found potential applications for the drug in
treatment of diabetic, respiratory and age-related diseases 
    ** Co has filed new provisional patent application covering
newfound uses of the drug 
    ** About 3.1 mln shares have been traded, compared with the
30-day average of about 944,000 shares 
    ** ANP up 53.85% this year as of last close 
    


 (Reporting by Harshita Swaminathan in Bengaluru)
 ((Harshita.Swaminathan@thomsonreuters.com))